Yves Pommier
Editor

DNA Topoisomerases
and Cancer

Humana Press
Preface

This book brings together a unique collection of chapters that provide detailed information on human topoisomerase s. It covers current knowledge on human DNA topoisomerases, their targeting by anticancer drugs and carcinogenic lesions, the clinical use of topoisomerase inhibitors and the various pathways and cellular responses involved in the repair of topoisomerase-mediated DNA damage.

Contributors to this book are world class scientists who have made key discoveries in the field. I wish to thank them for their time, enthusiasm and for making this book a collection of complementary articles covering the topoisomerase field both from basic biology and therapeutic viewpoints.

I dedicate this book to Dr. Kurt W. Kohn who in 1979 suggested that a topoisomerase should be the target of anticancer drugs. Kurt Kohn inspired me to work on DNA topoisomerases starting in 1981 and has remained a precious collaborator ever since.

Bethesda, MD

Yves Pommier
Contents

1 Introduction and Historical Perspective .............................................. 1
   Patrick Forterre

2 Human DNA Topoisomerase I:
   Structure, Enzymology and Biology ..................................................... 53
   James J. Champoux

3 Mitochondrial Topoisomerases ............................................................. 71
   Ilaria Dalla Rosa, Yves Pommier, and Hongliang Zhang

4 Structure and Mechanism of Eukaryotic Type IIA
   Topoisomerases ....................................................................................... 87
   James M. Berger and Neil Osheroff

5 Essential Functions of Topoisomerase IIIα in the Nucleus
   and Mitochondria ..................................................................................... 103
   Stefanie Hartman Chen, Jianhong Wu, and Tao-shih Hsieh

6 DNA Topoisomerase I and Illegitimate Recombination ..................... 119
   Céline Auzanneau and Philippe Pourquier

7 Topoisomerase-Induced DNA Damage ................................................ 145
   Yves Pommier and Neil Osheroff

8 Topoisomerases and Carcinogenesis:
   Topoisomerase IIIα and BLM ................................................................. 155
   Mounira Amor-Guéret and Jean-François Riou

9 Topoisomerases Inhibitors: A Paradigm
   for Interfacial Inhibition ...................................................................... 175
   Christophe Marchand and Yves Pommier

10 Topoisomerase I Inhibitors: Chemical Biology ................................. 185
    Beverly A. Teicher
11 Topoisomerase II Inhibitors: Chemical Biology ................................. 211
Anna Rogojina, Stefan Gajewski, Karim Bahmed,
Neil Osheroff, and John L. Nitiss

12 Topoisomerase I Inhibitors: Current Use and Prospects ............... 245
Yan Makeyev, Franco Muggia, Arun Rajan,
Giuseppe Giaccone, Takahisa Furuta, and Philippe Rougier

13 Topoisomerase II Inhibitors: Current Use and Prospects ............. 279
Olivier Mir, William Dahut, François Goldwasser,
and Christopher Heery

14 Transcriptional Stress by Camptothecin: Mechanisms and
Implications for the Drug Antitumor Activity ............................... 309
Giovanni Capranico, Laura Baranello, Davide Bertozzi,
and Jessica Marinello

15 Mechanisms Regulating Cellular Responses
to DNA Topoisomerase I-Targeted Agents .................................. 325
Piero Benedetti and Mary-Ann Bjornsti

16 Tyrosyl-DNA-Phosphodiesterase ............................................... 335
Thomas S. Dexheimer, Shar-yin N. Huang, Benu Brata Das,
and Yves Pommier

17 Ubiquitin and Ubiquitin-Like Proteins in Repair
of Topoisomerase-Mediated DNA Damage .................................... 355
Shyamal D. Desai

18 Repair of Topoisomerase II-Mediated DNA Damage: Fixing DNA Damage Arising from a Protein Covalently Trapped on DNA ................................................................. 381
John L. Nitiss, Eroica Soans, Jeffrey Berk, Aman Seth,
Margarita Mishina, and Karin C. Nitiss

19 Topoisomerases and Apoptosis .................................................... 409
Olivier Sordet and Stéphanie Solier

Index................................................................................................................ 437
Contributors

Mounira Amor-Guéret  Institut Curie, Centre de Recherche, Centre Universitaire Orsay, France

Céline Auzanneau  INSERM U916 VINCO, Institut Bergonié & University of Bordeaux, Bordeaux cedex, France

Karim Bahmed  Molecular Pharmacology Department, St. Jude Children’s Research Hospital, Memphis, TN, USA

Laura Baranello  “G. Moruzzi” Department of Biochemistry, University of Bologna, Bologna, Italy

Piero Benedetti  Department of Biology, University of Padova, Padua, Italy

James M. Berger  Department of Molecular and Cell Biology, QB3 Institute, University of California at Berkeley, Berkeley, CA, USA

Jeffrey Berk  Molecular Pharmacology Department, St. Jude Children’s Research Hospital, Memphis, TN, USA

Davide Bertozzi  “G. Moruzzi” Department of Biochemistry, University of Bologna, Bologna, Italy

Mary-Ann Bjornsti  Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA

Giovanni Capranico  “G. Moruzzi” Department of Biochemistry, University of Bologna, Bologna, Italy

James J. Champoux  Department of Microbiology, School of Medicine, University of Washington, Seattle, WA, USA

Stefanie Hartman Chen  Department of Biochemistry, Duke University Medical Center, Durham, NC, USA

William Dahut  Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Contributors

Benu Brata Das Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Shyamal D. Desai Department of Biochemistry and Molecular Biology, LSU Health Sciences Center-School of Medicine, New Orleans, LA, USA

Thomas S. Dexheimer National Chemical Genomic Center, National Institutes of Health, Rockville, MD, USA

Patrick Forterre Institut de Génétique et Microbiologie, Univ Paris-Sud, 91405, Orsay Cedex, France
CNRS UMR 8621, and Institut Pasteur, 25 rue du Docteur Roux, 75015, Paris, France

Takahisa Furuta Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Japan

Stefan Gajewski Institut für Molekulare Biowissenschaften, Karl Franzens Universität, Humboldtstrasse, Graz, Austria
Department of Structural Biology, St Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, USA

Giuseppe Giaccone Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA

François Goldwasser Department of Clinical Oncology, Hopital Cochin, Paris, France

Christopher Heery Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Tao-shih Hsieh Department of Biochemistry, Duke University Medical Center, Durham, NC, USA

Shar-yin N. Huang Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Yan Makeyev New York University Langone Medical Center, New York, NY, USA

Christophe Marchand Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Jessica Marinello “G. Moruzzi” Department of Biochemistry, University of Bologna, Bologna, Italy

Olivier Mir Department of Clinical Oncology, Hopital Cochin, Paris, France

Margarita Mishina Molecular Pharmacology Department, St. Jude Children’s Research Hospital, Memphis, TN, USA

Franco Muggia New York University Langone Medical Center, New York University, NY, USA
John L. Nitiss  Department of Biopharmaceutical Sciences, University of Illinois College of Pharmacy, IL, Chicago

Karin C. Nitiss  Molecular Pharmacology Department, St. Jude Children’s Research Hospital, Memphis, TN, USA

Neil Osheroff  Departments of Biochemistry and Medicine (Hematology/Oncology), School of Medicine, Vanderbilt University, Nashville, TN, USA

Yves Pommier  Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Philippe Pourquier  INSERM U916 VINCO, Institut Bergonie & University of Bordeaux, Bordeaux Cedex, France

Arun Rajan  Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA

Jean-François Riou  Régulation et Dynamique des Génomes, INSERM U565, Muséum National d’Histoire Naturelle, Paris, Cedex, France

Anna Rogojina  Molecular Pharmacology Department, St. Jude Children’s Research Hospital, Memphis, TN, USA

Philippe Rougier  University of Versailles, Ambroise Paré Hospital, Paris, France

Ilaria Dalla Rosa  Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Aman Seth  Molecular Pharmacology Department, St. Jude Children’s Research Hospital, Memphis, TN, USA

Eroica Soans  Molecular Pharmacology Department, St. Jude Children’s Research Hospital, Memphis, TN, USA

Stéphanie Solier  Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Olivier Sordet  Cancer Research Center of Toulouse, INSERM-Université de Toulouse, Institut Claudius Regaud, Toulouse Cedex, France

Beverly A. Teicher  Developmental Therapeutics Program, National Cancer Institute, Rockville, MD, USA

Jianhong Wu  Department of Biochemistry, Duke University Medical Center, Durham, NC, USA

Hongliang Zhang  Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA